Literature DB >> 17473913

Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice.

J Østergaard1, S Thiel, M Gadjeva, T K Hansen, R Rasch, A Flyvbjerg.   

Abstract

AIMS/HYPOTHESIS: An increasing amount of evidence indicates that mannose-binding lectin (MBL) plays a role in the development of diabetic nephropathy. The main objective of the study was to analyse whether MBL influences the effects of diabetes on the kidneys.
MATERIALS AND METHODS: In one group of wild-type mice and in one group of MBL double knockout mice we induced diabetes by the use of streptozotocin as a model of type 1 diabetes. Two groups of non-diabetic mice, wild-type and MBL knockout, were also included. By two-way ANOVA we evaluated if MBL modulated the effects of diabetes by testing the interaction between diabetes and MBL.
RESULTS: MBL interacted with the effects of diabetes on three outcome measures: kidney weight (p < 0.001), urinary albumin excretion (p = 0.001) and the expression of collagen IV alpha 1 (Col4a1) mRNA (p = 0.002). This means that the effects that diabetes normally has on these parameters were significantly modified by MBL. MBL showed a tendency to interact with the effects of diabetes on glomerular basement membrane thickness and total mesangial volume (p = 0.065 and p = 0.063, respectively). Glomerular volume and total mesangial volume were significantly smaller in animals lacking MBL than in wild-type animals (p = 0.006 and p = 0.047, respectively). CONCLUSIONS/
INTERPRETATION: These findings, for the first time, show that the degree of kidney alteration as a consequence of diabetes is modified by MBL. These findings support a pivotal role of MBL in the development of diabetic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473913     DOI: 10.1007/s00125-007-0686-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  46 in total

1.  Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy.

Authors:  M Saraheimo; C Forsblom; T K Hansen; A-M Teppo; J Fagerudd; K Pettersson-Fernholm; S Thiel; L Tarnow; P Ebeling; A Flyvbjerg; P-H Groop
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

Review 2.  Complement activation and diabetic vascular complications.

Authors:  Jakob Østergaard; Troels Krarup Hansen; Steffen Thiel; Allan Flyvbjerg
Journal:  Clin Chim Acta       Date:  2005-11       Impact factor: 3.786

3.  Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats.

Authors:  Dae Ryong Cha; Young Sun Kang; Sang Youb Han; Yi Hwa Jee; Kum Hyun Han; Jee Young Han; Young Sik Kim; Nan Hee Kim
Journal:  J Endocrinol       Date:  2004-10       Impact factor: 4.286

Review 4.  From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.

Authors:  Bieke F Schrijvers; An S De Vriese; Allan Flyvbjerg
Journal:  Endocr Rev       Date:  2004-12       Impact factor: 19.871

5.  Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease.

Authors:  Stephen Thomas; Johann Vanuystel; Gabriella Gruden; Verónica Rodríguez; Davina Burt; Luigi Gnudi; Barry Hartley; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

6.  Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy.

Authors:  Duraisamy Senthil; Goutam Ghosh Choudhury; Colby McLaurin; Balakuntalam S Kasinath
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

7.  Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation.

Authors:  Noriko Uesugi; Noriyuki Sakata; Masaomi Nangaku; Masatoshi Abe; Seikoh Horiuchi; Satoshi Hisano; Hiroshi Iwasaki
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

8.  Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.

Authors:  Edward D Verrier; Stanton K Shernan; Kenneth M Taylor; Frans Van de Werf; Mark F Newman; John C Chen; Michel Carrier; Axel Haverich; Kevin J Malloy; Peter X Adams; Thomas G Todaro; Christopher F Mojcik; Scott A Rollins; Jerrold H Levy
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

9.  Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.

Authors:  K Sharma; Y Jin; J Guo; F N Ziyadeh
Journal:  Diabetes       Date:  1996-04       Impact factor: 9.461

10.  Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency.

Authors:  P Garred; H O Madsen; B Hofmann; A Svejgaard
Journal:  Lancet       Date:  1995-10-07       Impact factor: 79.321

View more
  22 in total

Review 1.  Complement activation in progressive renal disease.

Authors:  Amy Fearn; Neil Stephen Sheerin
Journal:  World J Nephrol       Date:  2015-02-06

2.  Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study.

Authors:  Jakob A Østergaard; Steffen Thiel; Peter Hovind; Charlotte B Holt; Hans-Henrik Parving; Allan Flyvbjerg; Peter Rossing; Troels K Hansen
Journal:  Diabetologia       Date:  2014-07-28       Impact factor: 10.122

3.  Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes.

Authors:  T K Hansen; C Forsblom; M Saraheimo; L Thorn; J Wadén; P Høyem; J Østergaard; A Flyvbjerg; P-H Groop
Journal:  Diabetologia       Date:  2010-04-16       Impact factor: 10.122

Review 4.  Non-genetic mechanisms of diabetic nephropathy.

Authors:  Qiuxia Han; Hanyu Zhu; Xiangmei Chen; Zhangsuo Liu
Journal:  Front Med       Date:  2017-09-04       Impact factor: 4.592

5.  Functional variants in MBL2 are associated with type 2 diabetes and pre-diabetes traits in Pima Indians and the old order Amish.

Authors:  Yunhua L Muller; Robert L Hanson; Li Bian; Janel Mack; Xiaolian Shi; Ruth Pakyz; Alan R Shuldiner; William C Knowler; Clifton Bogardus; Leslie J Baier
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

Review 6.  The role of the complement system in metabolic organs and metabolic diseases.

Authors:  Julia Phieler; Ruben Garcia-Martin; John D Lambris; Triantafyllos Chavakis
Journal:  Semin Immunol       Date:  2013-05-17       Impact factor: 11.130

Review 7.  Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily.

Authors:  Allan Flyvbjerg
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

8.  Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes.

Authors:  M N Busche; M C Walsh; M E McMullen; B J Guikema; G L Stahl
Journal:  Diabetologia       Date:  2008-05-21       Impact factor: 10.122

9.  Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians.

Authors:  M A Siezenga; P K Chandie Shaw; R N van der Geest; T E Mollnes; M R Daha; T J Rabelink; S P Berger
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

10.  Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy.

Authors:  Mari A Kaunisto; Lisa Sjölind; Riitta Sallinen; Kim Pettersson-Fernholm; Markku Saraheimo; Sara Fröjdö; Carol Forsblom; Johan Fagerudd; Troels K Hansen; Allan Flyvbjerg; Maija Wessman; Per-Henrik Groop
Journal:  Diabetes       Date:  2009-04-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.